Navigation Links
T cell repertoire changes predictive of anti-CTLA-4 cancer immunotherapy outcome revealed
Date:5/28/2014

Sequenta, Inc. today announced publication of a study done in collaboration with researchers from UCSF and UCLA that used the company's proprietary LymphoSIGHT immune repertoire sequencing platform to investigate the effects of anti-CTLA-4 antibody on the number and types of T cells present in a patient's blood. The results, which appear in the May 28 issue of Science Translational Medicine, shed light on the mechanism of action of this type of cancer immunotherapy and suggest that immune repertoire sequencing could be used to predict which patients will have improved survival in response to treatment.

"Immune repertoire sequencing is a new tool that allows us to assess the totality and complexity of immune responses in ways not previously possible," said Lawrence Fong, M.D., Professor, Division of Hematology/Oncology, Department of Medicine, UCSF. "Our analysis of anti-CTLA-4 antibody treated patients using the LymphoSIGHT platform revealed that this therapy induces profound turnover and large-scale remodeling of the entire human T cell repertoire. These findings have implications for understanding how cancer immunotherapy works, which patients will benefit, and the etiology of side effects, such as autoimmune responses."

The researchers used next-generation sequencing to assess the impact of CTLA-4 blockade on changes to the T cell repertoire in 25 metastatic castration-resistant prostate cancer patients treated with ipilimumab and GM-CSF, 21 metastatic melanoma patients treated with tremelimumab, and nine untreated control subjects. Results showed that patients with longer survival had significantly lower numbers of T cell clones (sets of T cells that all express the same receptor) that decreased in frequency after treatment compared to patients with shorter survival. This association held for both the prostate cancer patients (p < 0.01) and the melanoma patients (p < 0.05).

"By leveraging the power of Sequenta's LymphoSIGHT platform for immune repertoire profiling, we and our collaborators have uncovered new aspects of the mechanism of action of anti-CTLA-4 monoclonal antibodies in human cancers," said Tom Willis, CEO of Sequenta. "We have also demonstrated the potential of next-generation sequencing analysis of the immune repertoire for identification of patterns that may predict clinical benefit of immunotherapies, which will be crucial for optimal use of currently available treatments and efficient development of new ones."


'/>"/>

Contact: Erin Davis
erin.davis@sequenta.com
415-640-9624
Sequenta Inc.
Source:Eurekalert

Related medicine news :

1. Yale Cancer Center studies find lifestyle changes improve biomarkers for breast cancer recurrence and mortality
2. Researchers ID changes that may occur in neural circuits due to cocaine addiction
3. TB lung infection causes changes in the diversity of gut bacteria in mice
4. Mount Sinai researchers identify changes that may occur in neural circuits due to addiction
5. Second opinion changes diagnosis from incurable to curable cancer
6. The Pael-R gene does not mediate the changes in rotenone-induced PD model cells
7. Changes in processing, handling could reduce commercial fishing injuries
8. DNA modifications measured in blood signal related changes in the brain
9. Epigenetic changes could explain type 2 diabetes
10. Researchers find changes to protein SirT1
11. NIH scientists map gene changes driving tumors in common pediatric soft-tissue cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... 28, 2016 , ... Greener Hydroponics is now offering a large selection of ... professional organic farmers and nurseries according to Sales Manager Joe Steele who says, “Now ... goal is to offer wholesale level pricing and ultra-fast shipping for growers of any ...
(Date:4/28/2016)... ... April 28, 2016 , ... In 2011, TIME magazine named Herr ... field of biomechatronics, technology that marries human physiology with electromechanics. He continues that work ... also the Founder of BionX , a leader in the field of prosthetic ...
(Date:4/28/2016)... (PRWEB) , ... April 28, ... ... leading provider of enterprise Data Center Infrastructure Management solutions, announces today the ... on feature enhancements in the area of capacity management and optimization, providing ...
(Date:4/28/2016)... , ... April 28, 2016 , ... One way to ... anything.” This is unfortunately true. But we toss the baby out with the bathwater ... brief provides tips for identifying higher-quality studies and otherwise making better use of education ...
(Date:4/28/2016)... , ... April 28, 2016 , ... USA Medical Card reminds us that May is ... a stroke is the fourth leading cause of death in the United States; someone has ... a quarter of them in individuals under 65 years old. A stroke is when ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... , April 27, 2016 ... ), a developer of a new generation of ... positive overall survival results for Paclical/Apealea in the ... 789 patients with epithelial ovarian cancer. These preliminary ... Paclical/Apealea in combination with carboplatin versus Taxol in ...
(Date:4/27/2016)... April 27, 2016 At the ... launch of a Phase 2 clinical study of its ... patients undergoing cochlear implantation (CI) surgery. This large, placebo-controlled, ... Germany and France ... ear at the time of surgery. "Despite advances in ...
(Date:4/26/2016)... CLEVELAND , April 26, 2016 ... is forecast to expand 4.9 percent annually to ... and other healthcare facilities to decrease rates of ... infection prevention supplies, equipment, and services.  Although declining, ... is significantly above targeted levels set by the ...
Breaking Medicine Technology: